Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

This study has been terminated.
(FDA Clinical Hold)
Sponsor:
Information provided by (Responsible Party):
GTx
ClinicalTrials.gov Identifier:
NCT01420861
First received: August 18, 2011
Last updated: April 23, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)


Condition Intervention Phase
Prostate Cancer
Drug: GTx-758
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy

Resource links provided by NLM:


Further study details as provided by GTx:

Primary Outcome Measures:
  • Decline in serum PSA [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: September 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1000 mg GTx-758
subjects will receive daily doses of 1000 mg GTx-758
Drug: GTx-758
two GTx 758 tablets per day

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be over 18 years of age
  2. Be able to communicate effectively with the study personnel
  3. Have histologically confirmed prostate cancer
  4. ECOG performance status of 0 to 2
  5. Have been treated with ADT(chemical or surgical) for at least 6 months
  6. Have castrate level of serum total testosterone (<50 ng/dL)
  7. Have a history of serum PSA response after initiation of ADT, serum PSA response is at least a 90% reduction in serum PSA to <10 ng/mL OR undetectable level of serum PSA (less tan or =0.2 ng/mL)
  8. Have rising serum PSA on two successive assessments at least 2 weeks apart and serum PSA levels ≥ 2 ng/mL or 2ng/mL and a 25% increase over the nadir after the initiation of ADT
  9. Be continued on androgen deprivation therapy throughout this study
  10. Give written informed consent prior to any study specific procedures
  11. Subjects must agree to use acceptable methods of contraception:

oIf their female partners are pregnant or lactating acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia) a condom with spermicidal foam/gel/film/cream/suppository should be used. oIf the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e. barrier method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}. oIf the female partner has undergone documented tubal ligation (female sterilization), a barrier method {condom used with spermicidal foam/gel/film/cream/suppository} should also be used. oIf the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and a barrier method {condom with spermicidal foam/gel/film/cream/suppository} should also be used.

Exclusion Criteria:

  1. Known hypersensitivity or allergy to estrogen or estrogen like drugs;
  2. Have symptomatic metastatic prostate cancer
  3. Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk;
  4. History of abnormal blood clotting, Factor V Leiden clotting disorder, thrombotic disease (venous or arterial thrombotic events such as history of stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE))
  5. Symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris, cardiac arrhythmia
  6. The presence of consistently abnormal laboratory values which are considered clinically significant. In addition, no subject with liver enzymes (ALT or AST) above 2 times the ULN, total bilirubin above 2 times the ULN, or serum creatinine above 1.5 ULN will be admitted to the study
  7. Received an investigational drug within a period of 90 days prior to enrollment in the study
  8. Received the study medication previously
  9. Currently taking testosterone, testosterone-like agents, or antiandrogens,including 5-alpha reductase inhibitors (may be eligible if allow a 6 week washout period after stopping antiandrogens);
  10. History of prior treatment of cancer chemotherapy agent (other than hormone therapy) or radiopharmaceutical for prostate cancer.
  11. Have taken ketoconazole within the previous 12 months prior to randomization into this study
  12. Have taken diethylstilbestrol or other estrogen products, ketoconazole, or abiraterone within the previous 12 months prior to randomization into this study
  13. Have taken body building or fertility supplements within 4 weeks of admission into the study
  14. Have been previously diagnosed with cancer (other than prostate cancer, superficial bladder cancer, or non-melanoma skin cancer).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01420861

Locations
United States, California
GTx Investigative Site
San Bernardino, California, United States, 92404
United States, Indiana
GTx Investigational Site
Jeffersonville, Indiana, United States, 47130
United States, New Mexico
GTx Investigative Site
Albuquerque, New Mexico, United States, 87109
United States, New York
GTx Investigative Site
Syracuse, New York, United States, 13210
United States, Pennsylvania
GTx Investigative Site
Bala Cynwyd, Pennsylvania, United States, 19004
United States, Texas
GTx Investigative Site
San Antonio, Texas, United States, 78229
United States, Virginia
GTx Investigative Site
Virginia Beach, Virginia, United States, 23462
Sponsors and Collaborators
GTx
Investigators
Study Director: Mitchell Steiner, MD GTx
  More Information

No publications provided

Responsible Party: GTx
ClinicalTrials.gov Identifier: NCT01420861     History of Changes
Other Study ID Numbers: G200707
Study First Received: August 18, 2011
Last Updated: April 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GTx:
castrate resistant

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 20, 2014